Hemab Therapeutics Stock

hemab.comHealthcareFounded: 2022

Hemab Therapeutics, founded in 2019, specializes in developing treatments for patients with bleeding and thrombotic disorders. Specifically, the company focuses on finding preventive treatments for less-common disorders for which fewer treatments are currently available. The company’s therapies are designed to accumulate, modulate, and make use of endogenous clotting factors in patients to form hemostatic plugs when it matters most.

Register for Details

For more details on financing and valuation for Hemab Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Hemab Therapeutics.

Register Today

Hemab Therapeutics investors also invested in these private companies

Team

Management Team

Benny Sørensen Ph.D
Chief Executive Officer
Mads Behrndt
Chief Financial Officer
Johan Faber Ph.D
Co-Founder & Chief Technology Officer
Thomas Stenfeldt
Co-Founder

Board Members

Camilla Hansen Ph.D
Novo Holdings
Dan Becker Ph.D
Access Biotechnology
Uya Chuluunbaatar Ph.D
Avoro Ventures

Other companies like Hemab Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$1.08B
Sector
 
 

News

While hemophilia has soaked up clinical attention and investor dollars for decades, it’s come at the expense of a range of intriguingly named but less well-known blood clotting disorders. That’s where Hemab Therapeutics comes in.
Hemab Therapeutics, a clinical-stage biotechnology company developing next-generation therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the first patient has been dosed in a Phase 1/2 study evaluating HMB-001 for the treatment of the severe bleeding disorder Glanzmann Thrombasthenia (Glanzmann).